6 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
8 May 24
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
5:00pm
-4, 2024 in Boston, Massachusetts.
“This year’s Endocrine Society meeting represents a major milestone for Crinetics as we present initial findings
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
=0.0003 80% 60% 28% 40% (5/18) 20% 0% Paltusotine Placebo *Endocrine Society Clinical Practice guidelines recommend target GH levels < 1.0 ng/mL
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
to 51 weeks. The results were featured in a poster presentation at the Society for Endocrinology BES congress, which can be found here.
Unveiled … of the American Society for Bone and Mineral Research (ASBMR). More information on the program and a copy of the poster can be found here.
Strengthened
8-K
CRNX
Crinetics Pharmaceuticals Inc
8 Nov 21
Other Events
8:53am
Society for Endocrinology BES congress in Edinburgh, Scotland. Patients who completed either of the Phase 2 ACROBAT Edge or Evolve studies including
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
5 Nov 21
Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:00am
. Details on the preclinical efforts supporting the program were presented in a late-breaking poster at the annual meeting of the American Society for Bone
8-K
EX-99.1
vcye6jnbk
13 May 19
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
4:10pm
- Prev
- 1
- Next